Response to hepatitis B vaccination in high risk population.
Article
in English
| IMSEAR
| ID: sea-112246
ABSTRACT
Hepatitis B vaccine is well established as very efficacious, but immune response to the vaccine is highly individual specific. A study involving fifty vaccinees was undertaken at the Hepatitis Laboratory, National Institute of Communicable Disease, Delhi. One ml (20 microgram) of Engerix B vaccine (recombinant yeast derived vaccine) was administered in the standard three dose schedule (0, 1 and 6 months). The sero-conversion of the vaccinees was 24%, 66%, 76% and 78% at 1 month, 6 months, 7 months, and 12 months respectively. There was no seroconversion in 22% of the vaccinees. Sero-conversion was assessed using Macro ELISA test (Ausab, Abbott Labs) for Anti HBs reactivity.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Main subject:
Time Factors
/
Female
/
Humans
/
Male
/
Enzyme-Linked Immunosorbent Assay
/
Vaccines, Synthetic
/
Biomarkers
/
Prospective Studies
/
Immunization Schedule
/
Vaccination
Type of study:
Etiology study
/
Observational study
/
Risk factors
Language:
English
Year:
2000
Type:
Article
Similar
MEDLINE
...
LILACS
LIS